49results about How to "Enhance anti-cancer efficacy" patented technology

The present invention provides a composition comprising a nicotine-containing material and an anti-cancer agent usable in the treatment and / or prevention or reduction of the risk of cancer and precancerous conditions as well as for preventing or reducing the risk of cancer recurrence. Furthermore, a composition comprising a nicotine-containing material and an anti-inflammatory agent usable in the treatment and / or prevention or reduction of the risk of inflammation, is provided. The nicotine containing composition can also include both an anti-cancer agent and an anti-inflammatory agent A device for administering the composition of the present invention to subjects can be a cigarette, smoking pipe, smokeless tobacco, electronic cigarette, transdermal patch or the like.

The present invention provides a pegylated lapatinib, an injection and a preparation method thereof, wherein the general formula of the pegylated lapatinib is defined in the specification, A is selected from a single-arm or multi-arm polyethylene glycol or poly ethylene glycol derivative, X is selected from the formula defined in the specification, Y and M are independently and respectively selected from double carboxylic acids having amino or corresponding acyl substituents, N is selected from an amino acid or peptide, LPT is lapatinib, a is 0 or 1, b is 0 or 1, c is 1 or 2, d is 1 or 2, and e is equal to the arm number of X. According to the present invention, the pegylated drug of lapatinib is synthesized, such that the lapatinib toxicity is reduced, the water solubility and the biological stability are improved, the drug resistance of cancer cells and cancer stem cells are avoided, the targeting property is enhanced, and the anticancer treatment effect is significantly improved.

A uniform microfluidized nanoemulsion is disclosed containing an anti-cancer agent, such as dacarbazine. The microfluidized nanoemulsion improves the combination's cell membrane permeability by at least four-fold over conventional nanoemulsion compositions, which significantly increases the intracellular concentration of anti-cancer agents. As a nanoemulsion, dacarbazine has a greater anti-cancer efficacy than when applied as a free solution.

The invention relates to a MRI (magnetic resonance imaging)-guided targeted photo-thermal agent and a preparation method of a chemotherapeutic system of the MRI-guided targeted photo-thermal agent. The method comprises the following steps: by using a hydrothermal method, preparing superparamagnetic ferroferric oxide nano-particles on PEI modified MoS2 in an in-situ preparation mode, thus obtaining a PEI modified MoS2 nano composite; preparing polyethylene glycol coupled targeting molecules by using EDC chemical; by using an EDC chemical, connecting polyethylene glycol with the targeting molecules to the PEI modified MoS2 nano composite in a covalent linkage mode; and through physical adsorption, loading a micromolecular anti-tumor drug on a carrier. The method disclosed by the invention is easy to operate and simple in step, and the prepared multi-functional MoS2 nano composite is good in biological compatibility, can be specifically gathered at tumor sites so as to effectively kill tumor cells, and can effectively integrate early diagnosis and late treatment so as to realize the integration of diagnosis and treatment of cancer treatment.

An emulsified injection for treating cancers is prepared from brucea fruit oil, medical emulsifier, isotonic agent and water through respectively dissolving oil phase and water phase, emulsifying and homogenizing.

The invention relates to the medicine field and discloses application of triptonide to anti-angiogenesis drugs. In-vitro and in-vivo tests for suppressing tumor neovascularization are carried out by adopting triptonide and the results show that the Chinese herbal medicine monomer triptonide can induce silencing of key genes for tumor neovascularization, promote tumor cell aging, differentiation and apoptosis, eliminate or reduce the neovascularization capacities of tumor cells, normalize and eliminate tumor vessels and improve the anticancer curative effects. Effective dose of triptonide and pharmaceutically acceptable auxiliary components can be used for preparing tablets, granules, capsules, suspension agents, syrup, emulsion or other common drug preparations. The drug preparations can be used for anti-angiogenesis. Besides, the extracts containing triptonide can be used for preparing the anti-angiogenesis drug preparations.

The invention relates to human body immunity improvement antifatigue health food and a preparation method thereof, and overcomes the technical problems of taking inconveniences and poor effects of the prior art, the human body immunity improvement antifatigue health food comprises the following components: by weight, 10-20 parts of cordyceps polysaccharides, 10-20 parts of ganoderma lucidum polysaccharides, 10-20 parts of spirulina, 5-15 parts of medlar and 1-3 parts of propolis, the invention also provides the preparation method thereof, and the preparation method can be widely used in the foodstuff preparation field.

The present invention relates to a polymer nanoparticle injection formulation composition containing rapamycin with improved water solubility, and more specifically, to an injection formulation composition containing rapamycin wherein water solubility is improved by solubilizing rapamycin having low water solubility with polymer nanoparticles, a preparation method thereof, and an anticancer composition for a combined use with radiotherapy.

The present invention provides methods for preventing, treating, and / or managing cancer, the method comprising administering to a subject in need thereof therapeutically effective amount of sodium meta arsenite that reduces or eliminates drug resistant cancer stem cell populations as well as drug resistant mature cancer cells.

Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble chelator, polyethylene glycol or polymer such as poly (1-glutamic acid) or poly (1-aspartic acid). Also disclosed are methods of using the compositions for treatment of tumors, autoimmune disorders such as rheumatoid arthritis and for prediction of paclitaxel uptake by tumors and radiolabeled DTPA-paclitaxel tumor imaging. Other embodiments include the coating of implantable stents for prevention of restenosis.

The invention discloses a compound docetaxel ester microsphere injection and a preparation method thereof, belonging to the technical field of medicines. The compound docetaxel ester microsphere injection is characterized by being prepared from the following raw materials in weight parts: 0.5 to 5 parts of docetaxel, 30-150 parts of Brucea javanica oil, 30-150 parts of middle-chain triglyceride, 10-30 parts of lecithin, 10-60 parts of polyethylene glycol surface active agents, 20-35 parts of glycerine and 700-950 parts of sterilized water for injection. The compound docetaxel ester microsphere injection of the invention is oil in water type microsphere preparation. The docetaxel as a main drug is coated in the Brucea javanica and middle-chain triglyceride compound oil phase of the oil in water type microsphere. The microsphere has a smaller grain diameter (which is lower than 100nm), and the preparation has better stability. The compound oil phase compositions play a cooperative anticancer role, and reduce the stimulation reaction of the injection and the side reactions such as hemolysis, allergy and the like. The invention has targeting function and increases the medicine effect.

The present invention provides a pegylated lapatinib, an injection and a preparation method thereof, wherein the general formula of the pegylated lapatinib is defined in the specification, A is selected from a single-arm or multi-arm polyethylene glycol or poly ethylene glycol derivative, X is selected from the formula defined in the specification, Y and M are independently and respectively selected from double carboxylic acids having amino or corresponding acyl substituents, N is selected from an amino acid or peptide, LPT is lapatinib, a is 0 or 1, b is 0 or 1, c is 1 or 2, d is 1 or 2, and e is equal to the arm number of X. According to the present invention, the pegylated drug of lapatinib is synthesized, such that the lapatinib toxicity is reduced, the water solubility and the biological stability are improved, the drug resistance of cancer cells and cancer stem cells are avoided, the targeting property is enhanced, and the anticancer treatment effect is significantly improved.

The invention relates to a medicine composition for treating breast cancer. Various natural Chinese herbs are adopted as raw materials. In the raw material components, radix codonopsis and bighead atractylodes rhizomes have the effect of improving the immunity of the human body, radix astragali has the effects of tonifying qi and the spleen, and inducing diuresis to alleviate edema, radix angelica sinensis, tubers of scirpus yagara ohw, curcuma phaeocaulis valeton, winged euonymus twigs and rhizoma corydalis have the effect of activating blood circulation to dissipate stasis, and radix actinidiae chinensis, spreading hedyotis herb, Chinese lobelia herb, lalang grass rhizomes, black nightshade herb, solanum lyratum thunb, herba rabdosiae rubescentis and coix seeds have the effect of clearing away heat and toxic materials, and have the effects of calming endogenous wind and relieving phlegm, clearing and activating the channels and collaterals, and counteracting toxic substances and removing stasis with the assistance of scorpions; all the medicine materials are in coordinate compatibility, mutually supplement one another, jointly achieve the effects of suppressing tumors and removing stasis, activating blood circulation to dissipate stasis, and activating meridians to stop pain, and are remarkable in treatment effect on breast cancer and capable of treating both the symptoms and root causes; besides, the medicine composition is a pure traditional Chinese preparation, is free of toxic or side effects, and improves the constitution of a patient, improves the immunity and relieves toxicity while inhibiting the growth and transfer of cancer cells, and thus the anti-cancer treatment effect is enhanced.

The present invention is directed to particular antibodies and fragments thereof that find use in the detection, prevention and treatment of diseases and disorders associated with abnormal angiogenesis. In particular, these antibodies detect tumor endothelial marker 8 (TEM8) in its native and cell-surface expressed form. Also disclosed are improved methods for producing monoclonal antibodies, as well as pharmaceutical compositions and kits.

The invention discloses an isosorbide mononitrate derivative, a preparation method thereof and an application thereof to tumor combined treatment as shown in the formula (II). Ester is formed by isosorbide mononitrate and fatty acid through an esterification reaction, so that lipid solubility can be improved, and then a lipid nanoparticle passive targeting drug delivery system is further prepared. Afterwards, the drug combination is conducted by lipid nanoparticles of an isosorbide mononitrate fatty acid derivative and nano targeting anticancer drugs, and the therapeutic effect of chemotherapeutic drugs is improved.

Theranostic agents useful for imaging and treating metastatic cancer are provided. The theranostic agents comprise a TMTP1 peptide conjugated to an albumin binding moiety to prolong circulation lifetime and a chelating agent to allow complexation of a diagnostic metal ion with the theranostic agent. The theranostic agent can be conjugated, for example, to a positron-emitting metal radionuclide suitable for PET imaging such as 64Cu, 68Ga, 44Sc, 86Y, 89Zr, or 82Rb; or a gamma-emitting metal radionuclide suitable for single photon emission computed tomography (SPECT) imaging such as 67Ga, 99mTc, 111In, or 177Lu. Alternatively, theranostic agents can be conjugated with a paramagnetic metal ion suitable for use in magnetic resonance imaging (MRI) such as manganese (e.g., Mn2+), iron (e.g., Fe3+, Fe2+) or gadolinium (e.g., Gd3+). Such theranostic agents show selective uptake by metastatic cancer cells and are useful for PET, SPECT, or MRI imaging of metastatic cells in vitro and in vivo.

A preparation method of javanica javanica oil emulsion injection, the javanica javanica oil emulsion injection contains 5-20g of pure javanica javanica oil per 100ml emulsion, 0.75-2.5g of a medicinally acceptable emulsifier, and an isotonic dose of medicine With an acceptable isotonic agent, the balance is water. The main preparation feature is to dissolve the oil phase components and the water phase separately, prevent the generation of impurities as much as possible during the preparation process, emulsify at a certain temperature to make colostrum, and then homogenize until the particle size of the emulsion reaches 50-300nm. Brucea Brucea Oil Emulsion Injection prepared by this method is being declared as a new drug under the trade name of An Ti Kang Injection. This Brucea Brucea Oil Emulsion Injection can ensure that the preparation can be directly injected intravenously, and improve the safe dosage of the drug, giving full play to the injection. The directional distribution of the emulsion and the directional effect of the lymphatic system are used to fully exert its therapeutic effect on cancer.

A protein nanocage formulation with enhanced mucus penetration capability and colloidal stability provides controlled delivery of therapeutic, prophylactic, or diagnostic agents to tumors. A dense coating of a surface altering agent such as polyethylene glycol on self-assembled protein nanocages enhances the rapid and uniform distribution of the formulation at mucosal tissues following topical administration, enhances circulation time following intravenous administration, and enhances penetration into hypoxic tumor cores. The density and the molecular weight of surface altering agents are selected to allow the protein nanocages to also bind to tumor cell receptors and release chemotherapeutic agents after tumor cell uptake. Agents delivered in the formulation have better efficacy compared to carrier-free agents. A method of making the protein nanocage formulation with enhanced mucus penetration and colloidal stability is also provided.

It has been established that exposure to cytotoxic doses of HSP90 inhibitor is broadly immunosuppressive, whereas continuous exposure to low-dosages of the same inhibitor exerts anti-tumor activity. The anti-tumor activity is mediated by the host immune system. Compositions and methods for continuous, low-dose exposure to HSP90 inhibitors in combination with one or more immunostimulatory agents for the treatment of cancer are described. Typically, the HSP90 inhibitor is administered in an amount that is between 1% and 20% of the clinically-determined maximum tolerate dose. The immunostimulatory agent can be administered simultaneously with the HSP90 inhibitor, or at some time before or after the HSP90 inhibitor. Compositions including a sub-toxic dose of HSP90 inhibitor in combination with an immunostimulatory agent in an amount effective to treat cancer are also provided.

A method for expanding a population of γδ T-cells is provided in which isolated activated Peripheral Blood Mononuclear Cells (PBMCs) are cultured in a medium comprising transforming growth factor beta (TGF-β) under conditions in which the production of effector γδ T-cells having therapeutic activity against malignant disease is favored. The use of TGF-β in the production of effector cells in particular Vγ9Vδ2 T-cells is also described and claimed.

Embodiments of the invention provide a method of improving the efficacy of an anti-cancer therapy and a method of treatment of cancer by normalizing angiogenesis in cancer. By enhancing the cell signaling pathway via a TRPV4 receptor in tumor endothelial cells, either by a TRPV4 agonist or by increasing the expression of TRPV4 in the tumor endothelial cells, the tumor endothelial cells behave normally and form normal angiogenic network for better anti-cancer therapy to the tumors.

The invention provides a medicine composition for treating cancer. The medicine composition is prepared from the following raw material medicines in parts by weight: 6-21 parts of camptotheca acuminate fruit, 5-20 parts of taxus chinensis, 5-25 parts of glabrous sarcandra herb, 10-30 parts of polyporus umbellatus, 20-50 parts of astragalus membranaceus, 9-30 parts of curcuma zedoary, 9-24 parts of turtle shell, 9-30 parts of herba patriniae, 9-30 parts of radix ranunculi ternati, 10-30 parts of ligusticum wallichii and 10-30 parts of angelica sinensis. The medicine composition is efficient, low in toxicity and free of obvious side effects after being taken for a long time, can be used for treating various solid tumor cancers such as lung cancer, liver cancer, lymph cancer, breast cancer and cervical cancer, can effectively improve the survival rate of patients, and has a very good clinical application prospect.

The present invention relates to novel peptides, compositions and uses thereof useful in tissue permeabilization, in particular in the context of treatment of cancer prevention and / or treatment or induction of an immune response, in particular via mucosal vaccination or anti-opioid treatment.

The invention discloses a niraparib oral liquid and a preparation method thereof and belongs to the field of drug production. The niraparib oral liquid comprises the following components in parts by weight: 10-20 parts of niraparib, 4-8 parts of diazepam, 3-6 parts of malt selenium, 3-6 parts of vitamin E, 20-40 parts of filler, 3-6 parts of colza oil, 4-8 parts of acetone and 130-150 parts of deionized water. The preparation method comprises the following steps: respectively corresponding dissolving diazepam and vitamin E in acetone and colza oil; uniformly mixing niraparib, deionized water and a part of filler; adding the prepared diazepam solution and vitamin E solution; adding malt selenium and the remaining filler, uniformly mixing and then filling, instantly sterilizing and packing,thereby acquiring the niraparib oral liquid. The niraparib oral liquid disclosed by the invention is capable of boosting the niraparib to exert anticancer curative effect and reducing the adverse reactions thereof.

The present invention provides a humanized monoclonal antibody against extracellular domain of human death receptor 5, comprising a light chain variable region, whose amino acid sequence has at least 90% identity with the amino acid sequence shown as SEQ ID NO: 1, a heavy chain variable region, whose amino acid sequence has at least 90% identity with the amino acid sequence shown as SEQ ID NO: 2, and constant region derived from human antibody. The present invention also provides nucleotide sequence encoding said humanized monoclonal antibody, a recombinant eukaryotic expression vector, a process for preparing the humanized monoclonal antibody, and the composition and use therefore. Said humanized monoclonal antibody of the present invention shows specific apoptosis-inducing activity against various cancer cells both in vivo and in vitro, and thus it can be used alone or in combination with natural ligand of DR5, apoptosis-inducing ligand associated with tumor nerosis factor or other medicaments for the treatment of a variety of cancers as well as other diseases associated with high DR5 expression.

A composite antisense nucleic acid medicine able to suppress the function of bcr3 / abl2 and VEGF genes features that the fusion gene bcr / abl and the vascular endothelial growth factor (VEGF) are its target and the antisense oligonucleotides (AS-ODNs) of said genes are acting on K562 cell line and k562 transfer tumor. It can be used to prepare the medicine for the pharmacotherapy and gene therapy of chronic granulocyte leukemia, and increasing the sensitivity of leukemia cells to chemicotherapeutic medicine.

This document provides materials and methods for treating cancer (e.g., PD-L1+ cancers). For example, methods and materials for using compositions (e.g., compositions containing a small bioactive S249 / T252 phospho-mimicking polypeptide of an RB polypeptide) to reduce PD-L1 expression within cancer cells are provided. In addition, methods and materials for using compositions (e.g., compositions containing a small bioactive S249 / T252 phospho-mimicking polypeptide of an RB polypeptide) in combination with other cancer treatment methods or agents to increase the effectiveness exhibited against the cancer within a mammal (e.g., a human) are provided.